Reperfusion therapies for acute ischemic stroke

Current Treatment Options in Neurology

Volumn 12, Issue 2, 2010, Pages 155-166

  Goldemund, David ^a   Mikulik, Robert ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ANGIONEUROTIC EDEMA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HOSPITAL; HUMAN; LOW DRUG DOSE; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; RECANALIZATION; REPERFUSION; REVIEW; THROMBECTOMY;

EID: 77953540507     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0064-y     Document Type: Review

References (39)

1. Ciccone A: Consent to thrombolysis in acute ischaemic stroke: from trial to practice. Lancet Neurol 2003, 2(6):375-378.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke.NEngl J Med 1995, 333(24):1581-1588.
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al.: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38(5):1655-1711.
4. Wahlgren N, AhmedN,Davalos A, et al.: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369(9558):275-282.
5. Hacke W, Donnan G, Fieschi C, et al.: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363(9411):768-774.
6. Hacke W, Kaste M, Bluhmki E, et al.: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008, 359(13):1317-1329. Compared with placebo, intravenous alteplase administered between 3 and 4.5 h after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke.
7. Wahlgren N, Ahmed N, Davalos A, et al.: Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008, 372 (9646):1303-1309.
8. Del Zoppo GJ, Saver JL, Jauch EC, et al.: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40(8):2945-2948.
9. Wolpert SM, Bruckmann H, Greenlee R, et al.: Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993, 14(1):3-13. (Pubitemid 23055914)
10. Alexandrov AV, Grotta JC: Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002, 59(6):862-867.
11. del Zoppo GJ, Poeck K, PessinMS, et al.: Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992, 32(1):78-86.
12. The European Stroke Organisation (ESO): Executive Committee and the ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25(5):457-507.
13. Furlan A, Higashida R, Wechsler L, et al.: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999, 282 (21):2003-2011.
14. Smith WS, Sung G, Starkman S, et al.: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005, 36 (7):1432-1438.
15. MattleHP, ArnoldM,GeorgiadisD, et al.: Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008, 39(2):379-383.
16. Ogawa A, Mori E, Minematsu K, et al.: Randomized trial of intraarterial infusion of urokinase within 6 h of middle cerebral artery stroke: the Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke 2007, 38 (10):2633-2639.
17. The IMS Study Investigators Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004, 35(4):904-911.
18. Smith WS: Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006, 27(6):1177-1182.
19. Flint AC, Duckwiler GR, Budzik RF, et al.: Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007, 38(4):1274-1280.
20. Bose A, Henkes H, Alfke K, et al.: The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008, 29(7):1409-1413.
21. Nedeltchev K, Brekenfeld C, Remonda L, et al.: Internal carotid artery stent implantation in 25 patients with acute stroke: preliminary results. Radiology 2005, 237 (3):1029-1037.
22. Jovin TG, Gupta R, Uchino K, et al.: Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate. Stroke 2005, 36(11):2426-2430.
23. Kirton A, Wong JH, Mah J, et al.: Successful endovascular therapy for acute basilar thrombosis in an adolescent. Pediatrics 2003, 112(3 Pt 1):e248-e251.
24. Lin DD, Gailloud P, Beauchamp NJ, et al.: Combined stent placement and thrombolysis in acute vertebrobasilar ischemic stroke. AJNR Am J Neuroradiol 2003, 24(9):1827-1833.
25. Coutts SB, Simon JE, Tomanek AI, et al.: Reliability of assessing percentage of diffusion-perfusion mismatch. Stroke 2003, 34(7):1681-1683.
26. Chalela JA, Kidwell CS, Nentwich LM, et al.: Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007, 369(9558):293-298.
27. Albers GW, Thijs VN, Wechsler L, et al.: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006, 60 (5):508-517.
28. Davis SM, Donnan GA, Parsons MW, et al.: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008, 7(4):299-309.
29. HackeW, AlbersG, Al-Rawi Y, et al.: TheDesmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase IIMRIbased 9-h window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36 (1):66-73.
30. Hacke W: Results from the phase III study of Desmoteplase In Acute Ischemic Stroke Trial 2 (DIAS 2). Presented at the 16th European Stroke Conference. Glasgow, Scotland; June 1, 2007.
31. Kane I, Sandercock P, Wardlaw J: Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J NeurolNeurosurg Psychiatry 2007, 78 (5):485-491.
32. Francis CW: Ultrasound-enhanced thrombolysis. Echocardiography 2001, 18(3):239-246.
33. Alexandrov AV, Molina CA, Grotta JC, et al.: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004, 351 (21):2170-2178.
34. Molina CA, Ribo M, Rubiera M, et al.: Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006, 37(2):425-429.
35. Alexandrov AV, Mikulik R, Ribo M, et al.: A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke 2008, 39(5):1464-1469.
36. Molina CA, Barreto AD, Tsivgoulis G, et al.: Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009, 66(1):28-38. This randomized, multicenter phase 2 trial of microspheres dose escalation with systemic thrombolysis shows that perflutren lipid microspheres at a dose of 1.4 mL can be safely combined with systemic tPA and ultrasound.
37. Lewandowski CA, Frankel M, Tomsick TA, et al.: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999, 30(12):2598-2605.
38. IMS II Trial Investigators: The Interventional Management of Stroke (IMS) II Study. Stroke 38 (7):2127-2135. The feasibility and safety of a combined intravenous and intra-arterial approach to recanalization for ischemic stroke was investigated in this trial. IMS II patients had significantly better outcomes at 3 months than placebo-treated participants in the NINDS rt-PA Stroke Trial for all end points and better outcomes than NINDS rt-PA-treated patients.
39. Shaltoni HM, Albright KC, Gonzales NR, et al.: Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke 2007, 38 (1):80-84.